RFG Advisory’s Protagonist Therapeutics PTGX Stock Holding History

RFG Advisory’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$725K	Buy	+5,143	New	+$733K	0.01%	719

Other funds holding PTGX

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

RFG Advisory's PTGX Position: Q3 2026 in Review

RFG Advisory opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 5,143 shares worth $725K. The stake represents 0.01% of the portfolio and ranks #719 among its holdings.

150 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

RFG Advisory held 5,143 shares of Protagonist Therapeutics worth $725K as of Q3 2026.
Protagonist Therapeutics was a new RFG Advisory position in Q3 2026.
Protagonist Therapeutics made up 0.01% of RFG Advisory's portfolio in Q3 2026, its #719 holding.
150 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on RFG Advisory's 13F filing for Q3 2026, filed 3 Nov 2026.